GlassScriptPhysician profile
Lynne Glaser
NPI 1275520694
$17,136.53
in general payments reported to CMS, 2019-2025
57 companies · $1,716 in 2025
The $1,716 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,188 · 2022: $3,329 · 2023: $3,701 · 2024: $4,202 · 2025: $1,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,607 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,607.18 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,792.99 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,592.71 | 2021-2025 | Farxiga, Lokelma, Airsupra |
| Amgen INC. | $1,288.45 | 2021-2025 | Otezla, Repatha, Evenity |
| Teva Pharmaceuticals USA, INC. | $1,130.92 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Pfizer INC. | $1,076.39 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $954.50 | 2022-2025 | Rexulti, Nuedexta |
| Vanda Pharmaceuticals INC. | $698.96 | 2022-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $651.21 | 2022-2025 | Ingrezza, Ongentys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $627.85 | 2022-2025 | Caplyta |
| Avanir Pharmaceuticals, INC. | $600.86 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $493.51 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.46 | 2021-2025 | Jardiance, Tradjenta |
| E.R. Squibb & Sons, L.L.C. | $425.37 | 2021-2025 | Eliquis, Camzyos |
| Alkermes, INC. | $372.78 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Lilly USA, LLC | $365.48 | 2021-2025 | Mounjaro, Jardiance, Kisunla |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $308.67 | 2021-2024 | Arexvy |
| Novartis Pharmaceuticals Corporation | $285.55 | 2022-2025 | |
| Novo Nordisk INC | $276.06 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $274.46 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $254.22 | 2022-2023 | |
| Astellas Pharma US INC | $248.57 | 2021-2023 | Veozah, Myrbetriq |
| Phathom Pharmaceuticals, INC. | $246.35 | 2024-2025 | Voquezna |
| Abbott Laboratories | $214.15 | 2023-2025 | Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $209.64 | 2021-2023 | |
| Exact Sciences Corporation | $199.10 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.90 | 2021-2025 | Xifaxan, Trulance |
| Mylan Specialty L.P. | $181.00 | 2021-2024 | Yupelri |
| Amarin Pharma, INC. | $166.13 | 2021-2022 | |
| Axsome Therapeutics, INC. | $164.30 | 2022-2023 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $138.55 | 2021-2022 | |
| Cmp Pharma, INC. | $115.76 | 2021-2023 | Tadliq, Norliqva, Carospir |
| Idorsia Pharmaceuticals US INC | $106.47 | 2022-2023 | Quviviq |
| Acadia Pharmaceuticals INC | $103.51 | 2022 | |
| Inspire Medical Systems, INC. | $101.55 | 2024-2025 | Inspire |
| Merck Sharp & Dohme LLC | $94.59 | 2021-2023 | Gardasil 9 |
| Eisai INC. | $90.57 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $83.50 | 2024 | Aptiom |
| Kowa Pharmaceuticals America, INC. | $77.49 | 2021-2023 | Seglentis |
| Esperion Therapeutics, INC. | $70.89 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.38 | 2022 | |
| Ardelyx, INC. | $38.56 | 2024-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $25.86 | 2025 | Vowst |
| Ucb, INC. | $25.44 | 2024 | Briviact |
| Biogen, INC. | $22.43 | 2021 | |
| Verona Pharma, INC. | $22.18 | 2025 | Ohtuvayre |
| Lundbeck LLC | $21.96 | 2023 | Brintellix |
| Dexcom, INC. | $21.75 | 2024 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $21.29 | 2025 | Watchman Access System |
| Urovant Sciences INC | $20.17 | 2021 | |
| Insightec,INC | $19.74 | 2022 | |
| Hikma Pharmaceuticals USA | $18.44 | 2021 | |
| Indivior INC. | $18.00 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.97 | 2025 | Onpattro |
| Ibsa Pharma INC. | $15.12 | 2022 | |
| Cequr Corporation | $14.43 | 2022 | |
| Bausch Health US, LLC | $14.30 | 2022 | |
| Paratek Pharmaceuticals, INC. | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynne Glaser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.